Athersys was started about 25 years ago and is currently developing MultiStem®, a proprietary stem cell product for the treatment of diseases and conditions in the neurological, inflammatory, and immune areas. The company has a clinical trial underway in each of those areas and is conducting studies in the U.S. and internationally. “Our MultiStem product […]

DocWire News recently talked to Spiro Rombotis, CEO of Cyclacel Pharmaceuticals, Inc., a company developing innovative therapies that target various phases of cell control for treating advanced cancers, among other serious diseases. Mr. Rombotis discussed the strides his company is making in developing and testing targeted therapies that may actually drive cancer cells “to commit suicide.” […]

Manufacturing issues are common with regenerative medicines. And so it goes for PolarityTE’s investigational new drug submission for SkinTE. On Tuesday the Salt Lake Salt Lake City biotech revealed that it has put its investigational new drug (IND) application on hold in chronic cutaneous ulcers to address chemistry, manufacturing and control (CMC) issues raised by the agency. The […]